Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tyvyt

- PMLiVE

Merck chalks up another win for Keytruda in lung cancer

Becomes the first PD-1 inhibitor to improve OS in NSCLC patients when combined with chemo

- PMLiVE

Novartis bags new breakthrough status for Kisqali in breast cancer

The Swiss pharma group’s treatment will rival Lilly’s Verzenio and Pfizer’s Ibrance if approved

AstraZeneca AZ

Clock starts ticking on AZ’s first-line lung cancer filing in US

FDA priority review of oncology treatment Tagrisso begins

Sanofi reception

FDA approves Sanofi’s follow-on version of Lilly’s Humalog

French pharma firm hopes Admelog will make a significant commercial impact in 2018

- PMLiVE

Data backs up Roche’s Tecentriq/Avastin combo in lung cancer

Results will be used to pursue a first-line indication in NSCLC

Lilly appoints Philip Johnson to senior VP and treasurer

He currently serves as VP, investor relations at the pharma company

- PMLiVE

Lung cancer data gives Roche’s Tecentriq a boost

Will help its PD-L1 inhibitor compete with Merck & Co’s Keytruda

- PMLiVE

Merck pulls Keytruda filing in Europe, despite US approval

Phase II KeyNote-0241 trial results failed to win over the EMA

- PMLiVE

Lilly mulls divestment of its animal health operations

Pharma firm is due to make a final decision on Elanco in 2018

- PMLiVE

MSD touts Keytruda first-line promise in NSCLC

Says patients on the drug more than doubled median OS compared to chemo

Lilly strengthens team with in-house promotions

And two senior leaders retire

Eli Lilly HQ

Prospects for Lilly’s Verzenio hit by botched lung cancer trial

The CDK 4/6 inhibitor failed to improve overall survival in a late-stage study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links